首页|贝伐珠单抗联合化疗致晚期结直肠癌患者心脏毒性的真实世界研究

贝伐珠单抗联合化疗致晚期结直肠癌患者心脏毒性的真实世界研究

扫码查看
目的 探讨贝伐珠单抗联合化疗对晚期结直肠癌患者心脏指标的影响。方法 选取南昌大学第一附属医院 2020年 1 月 1 日至 2022 年 12 月 31 日收治的 215 例晚期结直肠癌患者。根据是否使用贝伐珠单抗将患者分为联合贝伐珠单抗化疗组(A组,138 例)和单纯化疗组(B组,77 例)。对A组进行亚组分析:根据化疗周期次数划分为两个阶段,随后排除A、B两组中具有既往心血管危险因素的患者,分别记为C组和D组,对其进行亚组分析:比较患者特征、用药前后心肌酶谱、血压及心电图变化情况。结果 1。A、B两组患者临床特征差异无统计学意义(P>0。05)。2。心电图异常率比较:A组明显高于B组(P<0。05);亚组分析表明,C组较D组差异有统计学意义(P>0。05)。3。心肌酶谱变化:A组肌酸激酶(CK)、肌酸激酶同工酶(CK-MB)和乳酸脱氢酶(LDH)水平均有所增加,而B组没有明显变化,且两组间CK-MB和LDH差异有统计学意义(P>0。05);亚组分析示:患者治疗第二阶段血压较第一阶段升高明显(P>0。05);C组CK、CK-MB、LDH较D组差异无统计学意义(P>0。05)。结论 贝伐珠单抗导致心脏损伤与使用次数相关,CK-MB、LDH、心电图可作为早期发现心脏损伤的重要检测手段。
Real-world Study of Cardiotoxicity in Patients with Advanced Colorectal Cancer due to Bevacizumab-combination Chemotherapy
Objective To investigate the effect of bevacizumab(BVZ)in combination with chemotherapy on cardiac indexes of patients with advanced colorectal cancer.Methods A total of 215 patients with advanced colorectal cancer who were hospitalised at The First Affiliated Hospital of Nanchang University between 1 January 2020 and 31 December 2022 were selected.Patients were divided into two groups according to whether or not BVZ was used:the group with combined BVZ chemotherapy(group A,n=138)and the group with chemotherapy alone(group B,n=77).Within group A,a subgroup analysis was performed based on the number of chemotherapy cycles.In addition,patients with pre-existing cardiovascular risk factors were excluded from groups A and B and further subdivided into subgroups C and D for the analysis.Patient characteristics,changes in cardiac enzyme profiles,blood pressure measurements and electrocardiograms before and after drug administration were compared.Results 1.There was no significant difference in the clinical characteristics of patients in groups A and B(P>0.05).2.Comparison of electrocardiogram abnormality rate:group A was significantly higher than group B(P<0.05);subgroup analysis showed a significant increase in group C compared with group D(P<0.05).3.Changes in cardiac enzyme profiles showed increased levels of CK-MB,CK and LDH in group A,while there was no significant change in group B.In addition,there were significant differences in CK-MB and LDH between the two groups(P<0.05).Subgroup analysis showed that:the blood pressure of patients in the second stage of treatment was significantly higher than that in the first stage(P<0.05);the differences in CK,CK-MB,and LDH in group C compared with that in group D were not significant(P>0.05).Conclusion The use of BVZ is associated with cardiac injury,which depends on the frequency of administration.The measurement parameters including CK-MB,LDH and electrocardiogram may serve as important tests for the early detection of cardiac injury.

BevacizumabColorectal cancerCardiac toxicityAdverse reactionsBiomarkers

王佳惠、谢梦棋、黄伟林、黎军和、陈璿瑛

展开 >

南昌大学药学院,江西 南昌 330006

南昌大学第一附属医院,江西 南昌 330006

贝伐珠单抗 结直肠癌 心脏毒性 不良反应 标志物

2024

药品评价
江西省药学会

药品评价

影响因子:0.672
ISSN:1672-2809
年,卷(期):2024.21(3)